From taste hedonics to motivational drive: Central -opioid receptors and binge-eating behaviour

International Journal of Neuropsychopharmacology

Volumn 12, Issue 7, 2009, Pages 995-1008

  Nathan, Pradeep J ^a,b,c,d   Bullmore, Edward T ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c MONASH UNIVERSITY   (Australia)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

opioid receptor; Binge eating; Binge eating disorder; Hedonic; Motivation

Indexed keywords

ATOMOXETINE; BETA ENDORPHIN; CITALOPRAM; DEXFENFLURAMINE; DOPAMINE; DYNORPHIN; ENDORPHIN; ENKEPHALIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; LY 255582; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST; NALMEFENE; NALOXONE; NALTREXONE; OPIATE ANTAGONIST; SERTRALINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG; ZONISAMIDE;

APPETITE; BINGE EATING DISORDER; BULIMIA; CLINICAL TRIAL; DOPAMINE RELEASE; DRUG EFFECT; FOOD INTAKE; HUMAN; MOTIVATION; NONHUMAN; NUCLEUS ACCUMBENS; OBESITY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; REWARD; TASTE;

ANIMALS; APPETITE REGULATION; BINGE-EATING DISORDER; BRAIN; BULIMIA; DRIVE; FEEDING BEHAVIOR; HUMANS; LIGANDS; MODELS, ANIMAL; NARCOTIC ANTAGONISTS; OPIOID PEPTIDES; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION; TASTE;

EID: 69749084651     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114570900039X     Document Type: Review

References (180)

1. Alger SA, Schwalberg MD, Bigauette JM, Michalek AV, et al. (1991). Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behaviour in normoweight bulimic and obese, binge-eating subjects. American Journal of Clinical Nutrition 53, 865-871.
2. APA (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington DC: American Psychiatric Association.
3. Apfelbaum M, Mandenoff A (1981). Naltrexone suppresses hyperphagia induced in the rat by a highly palatable diet. Pharmacology Biochemistry Behaviour 15, 89-91.
4. Appolinario JC, Bacaltchuk J, Sichieri R, Claudino AM, et al. (2003). A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Archives of General Psychiatry 60, 1109-1116.
5. Arbisi PA, Billington CJ, Levine AS (1999). The effect of naltrexone on taste detection and recognition threshold. Appetite 32, 241-249.
6. Arnold LM, McElroy SL, Hudson JL, Welge JA, et al. (2002). A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. Journal of Clinical Psychiatry 63, 1028-1033.
7. Atkinson RL, Berke LK, Drake CR, Bibbs ML, et al. (1985). Effects of long-term therapy with naltrexone on body weight in obesity. Clinical Pharmacology and Therapeutics 38, 419-422.
8. Avena NM (2007). Examining the addictive-like properties of binge eating using an animal model of sugar dependence. Experimental and Clinical Psychopharmacology 15, 481-491.
9. Bakshi VP, Kelley AE (1993). Feeding induced by opioid stimulation of the ventral striatum: role of opiate receptor subtypes. Journal of Pharmacology and Experimental Therapeutics 265, 1253-1260.
10. Baldo BA, Kelley AE (2007). Discrete neurochemical coding of distinguishable motivational processes: insights from nucleus accumbens control of feeding. Psychopharmacology 191, 439-459.
11. Barbano MF, Cador M (2006). Differential regulation of the consummatory, motivational and anticipatory aspects of feeding behaviour by dopaminergic and opioidergic drugs. Neuropsychopharmacology 31, 1371-1381.
12. Barnes MJ, Holmes G, Primeaux SD, York DA, et al. (2006). Increased expression of mu opioid receptors in animals susceptible to diet-induced obesity. Peptides 27, 3292-3298.
13. Barnes MJ, Lapanowski K, Conley A,Rafols JA, et al. (2003). High fat feeding is associated with increased blood pressure, sympathetic nerve activity and hypothalamic mu opioid receptors. Brain Research Bulletin 61, 511-519.
14. Barnes MJ, Primeaux SD, Bray GA (2008). Food deprivation increases the mRNA expression of m-opioid receptors in the ventral medial hypothalamus and arcuate nucleus. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 295, 1385-1390.
15. Bart G, Heilig M, LaForge KS, Pollak L, et al. (2004). Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Molecular Psychiatry 9, 547-549.
16. Bassareo V, Di Chiara G (1997). Differential influence of associative and nonassociative learning mechanisms on the responsiveness of prefrontal and accumbal dopamine transmission to food stimuli in rats fed ad libitum. Journal of Neuroscience 17, 851-861.
17. Bassareo V, Di Chiara G (1999). Modulation of feeding-induced activation of mesolimbic dopamine transmission by appetitive stimuli and its relation to motivational state. European Journal of Neuroscience 11, 4389-4397.
18. Bencherif B, Guarda AS, Colantuoni C, Ravert HT, et al. (2005). Regional mu-opioid receptor binding in insular cortex is decreased in bulimia nervosa and correlates inversely with fasting behaviour. Journal of Nuclear Medicine 46, 1349-1351.
19. 11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biological Psychiatry 55, 255-262.
20. Berridge KC (1996). Food reward: brain substrates of wanting and liking. Neuroscience and Biobehavioral Reviews 20, 1-25.
21. Bertino M, Beauchamp GK, Engelman K (1991). Naltrexone, an opioid blocker, alters taste perception and nutrient intake in humans. American Journal of Physiology 261, R59-R63.
22. Bi S, Robinson BM, Moran TH (2003). Acute food deprivation and chronic food restriction differentially affect hypothalamic NPY mRNA expression. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 285, R1030-R1036.
23. Bodnar RJ, Glass MJ, Ragnauth A, Cooper ML (1995). General, mu and kappa opioid antagonists in the nucleus accumbens alter food intake under deprivation, glucoprivic and palatable conditions. Brain Research 700, 205-212.
24. Bodnar RJ, Lamonte N, Israel Y, Kandov Y, et al. (2005). Reciprocal opioid-opioid interactions between the ventral tegmental area and nucleus accumbens regions in mediating mu agonist-induced feeding in rats. Peptides 26, 621-629.
25. Bond C, LaForge KS, Tian M, Melia D, et al. (1998). Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proceedings of the National Academy of Sciences USA 95, 9608-9613.
26. Cardinal RN, Parkinson JA, Hall J, Everitt BJ (2002). Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. Neuroscience and Biobehavioral Reviews 26, 321-352.
27. Chang GQ, Karatayev O, Ahsan R, Gaysinskaya V, et al. (2007). Dietary fat stimulates endogenous enkephalin and dynorphin in the paraventricular nucleus: role of circulating triglycerides. American Journal of Physiology, Endocrinology and Metabolism 292, E561-E570.
28. Chang GQ, Karatayev O, Davydova Z, Leibowitz SF (2004). Circulating triglycerides impact on orexigenic peptides and neuronal activity in hypothalamus. Endocrinology 145, 3904-3912.
29. Chefer VI, Kieffer BL, Shippenberg TS (2003). Basal and morphine-evoked dopaminergic neurotransmission in the nucleus accumbens of MOR- and DOR-knockout mice. European Journal of Neuroscience 18, 1915-1922.
30. Chen RZ, Huang RR, Shen CP, MacNeil DJ, et al. (2004). Chronic administration of nalmefene leads to increased food intake and body weight gain in mice. European Journal of Pharmacology 495, 63-66.
31. Cleary J, Weldon DT, O'Hare E, Billington C, et al. (1996). Naloxone effects on sucrose-motivated behavior. Psychopharmacology 126, 110-114.
32. Colantuoni C, Schwenker J, McCarthy J, Rada P, et al. (2001). Excessive sugar intake alters binding to dopamine and mu-opioid receptors in the brain. Neuroreport 12, 3549-3552.
33. Cole JL, Leventhal L, Pasternak GW, Bowen WD, et al. (1995). Reductions in body weight following chronic central opioid receptor subtype antagonists during development of dietary obesity in rats. Brain Research 678, 168-176.
34. Cooper SJ (1980). Naloxone: effects on food and water consumption in the nondeprived and deprived rat. Psychopharmacology 71, 1-6.
35. Cooper SJ (1983). Effects of opiate agonists and antagonists on fluid intake and saccharin choice in the rat. Neuropharmacology 22, 323-328.
36. Cooper SJ, Barber DJ, Barbour-McMullen J (1985). Selective attenuation of sweetened milk consumption by opiate receptor antagonists in male and female rats of the Roman strains. Neuropeptides 5, 349-352.
37. Cooper SJ, Turkish S (1989). Effects of naltrexone on food preference and concurrent behavioral responses in food deprived rats. Pharmacology Biochemistry and Behavior 33, 17-20.
38. Corwin RL (2006). Bingeing rats: a model of intermittent excessive behavior? Appetite 46, 11-15.
39. Cottone P, Sabino V, Steardo L, Zorrilla EP (2008). Opioid-dependent anticipatory negative contrast and binge-like eating in rats with limited access to highly preferred food. Neuropsychopharmacology 33, 524-535.
40. Cowen MS, Lawrence AJ (1999). The role of opioid-dopamine interactions in the induction and maintenance of ethanol consumption. Progress in Neuropsychopharmacology and Biological Psychiatry 23, 1171-1212.
41. Cunningham ST, Kelley AE (1992). Opiate infusion into nucleus accumbens: contrasting effects on motor activity and responding for conditioned reward. Brain Research 588, 104-114.
42. Davis CA, Levitan RD, Reid C, Carter JC, et al. (2009). Dopamine for 'wanting' and opioids for 'liking': a comparison of obese adults with and without binge eating. Obesity. Published online: 12 March 2009. doi: 10.1038/ oby.2009.52.
43. Davis JM, Lowy MT, Yim GKW, Lamb DR, et al. (1983). Relationship between plasma concentrations of immunoreactive beta-endorphin and food intake in rats. Peptides 4, 79-83. De Zwaan M, Mitchell JE (1992a). Binge eating in the obese. Annals in Medicine 24, 303-308.
44. De Zwaan M, Mitchell JE (1992b). Opiate antagonists and eating behaviour in humans: a review. Journal of Clinical Pharmacology 32, 1060-1072.
45. Devlin MJ, Goldfein JA, Petkova E, Jiang H, et al. (2005). Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder. Obesity Research 13, 1077-1088.
46. Drewnowski A, Krahn DD, Demitrack MA, Nairn K, et al. (1992). Taste responses and preferences for sweet high-fat foods: evidence for opioid involvement. Physiology and Behavior 51, 371-379.
47. Drewnowski A, Krahn DD, Demitrack MA, Nairn K, et al. (1995). Naloxone, an opiate blocker, reduces the consumption of sweet high-fat foods in obese and lean female binge eaters. American Journal of Clinical Nutrition 61, 1206-1212.
48. Evans KR, Vaccarino FJ (1990). Amphetamine- and morphine-induced feeding: evidence for involvement of reward mechanisms. Neuroscience and Biobehavioural Reviews 14, 9-22.
49. Fantino M, Hosotte J, Apfelbaum M (1986). An opioid antagonist, naltrexone, reduces preference for sucrose in humans. American Journal of Physiology 251, R91-R96.
50. Fletcher BC, Pine KJ, Woodbridge Z, Nash A (2007). How visual images of chocolate affect the craving and guilt of female dieters. Appetite 48, 211-217.
51. Fruzzetti F, Bersi C, Parrini D, Ricci C, et al. (2002). Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. Fertility and Sterility 77, 936-944.
52. Gambarana C, Masi F, Leggio B, Grappi S, et al. (2003). Acquisition of a palatable-food-sustained appetitive behavior in satiated rats is dependent on the dopaminergic response to this food in limbic areas. Neuroscience 121, 179-187.
53. Giraudo SQ, Grace MK, Welch CC, Billington CJ, et al. (1993). Naloxone's anorectic effect is dependent upon the relative palatability of food. Pharmacology, Biochemistry and Behavior 46, 917-921.
54. Glass MJ, Briggs JE, Billington CJ, Kotz CM, et al. (2002). Opioid receptor blockade in rat nucleus tractus solitarius alters amygdala dynorphin gene expression. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 283, R161-R167.
55. Glass MJ, Grace MK, Cleary JP, Billington CJ, et al. (1996). Potency of naloxone's anorectic effect in rats is dependent on diet preference. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 271, R217-R221.
56. Glass MJ, Grace MK, Cleary JP, Billington CJ, et al. (2001). Naloxone's effect on meal microstructure of sucrose and cornstarch diets. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 281, R1605-R1612.
57. Golay A, Laurent-Jaccard A, Habicht F, Gachoud J, et al. (2005). Effect of orlistat in obese patients with binge eating disorder. Obesity Research 10, 1701-1708.
58. Gomes I, Gupta A, Filipovska J, Szeto HH, et al. (2004). A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proceedings of the National Academy of Sciences USA 101, 5135-5139.
59. Gomes I, Jordan BA, Gupta A, Trapaidze N, et al. (2000). Heterodimerization of mu and delta opioid receptors: A role in opiate synergy. Journal of Neuroscience 20, RC110, 1-5.
60. Gonzalez VM, Vitousek KM (2004). Feared food in dieting and non-dieting young women: a preliminary validation of the Food Phobia Survey. Appetite 43, 155-173.
61. Gorelick DA, Kim YK, Bencherif B, Boyd SJ, et al. (2005). Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biological Psychiatry 57, 1573-1582.
62. Grilo CM, Masheb RM, Wilson GT (2005). Efficacy of cognitive behavioural therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison. Biological Psychiatry 57, 301-309.
63. Grucza RA, Przybeck TR, Cloninger CR (2007). Prevalence and correlates of binge eating disorder in a community sample. Comprehensive Psychiatry 48, 124-131.
64. Guerdjikova AI, McElroy SL, Kotwal R, Welge JA, et al. (2008). High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial. Human Psychopharmacology 23, 1-11.
65. Guido M, Pavone V, Ciampelli M, Murgia F, et al. (1998). Involvement of ovarian steroids in the opioid-mediated reduction of insulin secretion in hyperinsulinemic patients with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 83, 1742-1745.
66. Gupta A, Décaillot FM, Devi LA (2006). Targeting opioid receptor heterodimers: strategies for screening and drug development. AAPS Journal 8, E153-E159.
67. Hadjimarkou MM, Singh A, Kndov Y, Israel Y, et al. (2004). Opioid involvement in food deprivation-induced feeding: evaluation of selective antagonist and antisense oligodeoxynucleotide probe effects in mice and rats. Journal of Pharmacology and Experimental Therapeutics 311, 1188-1202.
68. Hagan MM, Chandler PC, Wauford PK, Rybak RJ, et al. (2003). The role of palatable food and hunger as trigger factors in an animal model of stress induced binge eating. International Journal of Eating Disorders 34, 183-197.
69. Hagan MM, Holguin FD, Cabello CE, Hanscom DR, et al. (1997). Combined naloxone and fluoxetine on deprivation-induced binge eating of palatable foods in rats. Pharmacology Biochemistry and Behavior 58, 1103-1107.
70. Hagan MM, Wauford PK, Chandler PC, Jarrett LA, et al. (2002). A new animal model of binge eating: key synergistic role of past caloric restriction and stress. Physiology and Behavior 77, 45-54.
71. Hanlon EC, Baldo BA, Sadeghian K, Kelley AE (2004). Increases in food intake or food-seeking behavior induced by GABAergic, opioid, or dopaminergic stimulation of the nucleus accumbens: is it hunger? Psychopharmacology 172, 241-247.
72. Hayward MD, Pintar JE, Low MJ (2002). Selective reward deficit in mice lacking beta-endorphin and enkephalin. Journal of Neuroscience 22, 8251-8258.
73. Hayward MD, Shaich-Borg A, Pintar JE, Low MJ (2006). Differential involvement of endogenous opioids in sucrose consumption and food reinforcement. Pharmacology Biochemistry and Behaviour 85, 601-611.
74. Heinz A, Reimold M, Wrase J, Hermann D, et al. (2005). Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Archives of General Psychiatry 62, 57-64.
75. Herz A (1998). Opiod reward mechanisms: a key role in drug abuse. Canadian Journal of Physiology and Pharmacology 76, 252-258.
76. Hetherington MM, Vervaet N, Blass E, Rolls BJ (1991). Failure of naltrexone to affect the pleasantness or intake of food. Pharmacology Biochemistry and Behavior 40, 185-190.
77. Holtzman SG (1979). Suppression of appetitive behaviour in the rat by naloxone: lack of prior morphine dependence. Life Sciences 24, 219-226.
78. Howard CE, Porzelius LK (1999). The role of dieting in binge eating disorder: etiology and treatment implications. Clinical Psychology Review 19, 25-44.
79. Hudson JI, Hiripi E, Pope HG, Kessler Jr. RC (2007). The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biological Psychiatry 61, 348-358.
80. Hudson JI, McElroy SL, Raymond NC, Crow S, et al. (1998). Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. American Journal of Psychiatry 155, 1756-1762.
81. Inoue K, Zorrilla EP, Tabarin A, Valdez GR, et al. (2004). Reduction of anxiety after restricted feeding in the rat: implication for eating disorders. Biological Psychiatry 55, 1075-1081.
82. Jarosz PA, Kessler JT, Sekhon P, Coscina DV (2007). Conditioned place preferences (CPPs) to high-caloric 'snack foods' in rat strains genetically prone vs. resistant to diet-induced obesity: resistance to naltrexone blockade. Pharmacology Biochemistry and Behavior 86, 699-704.
83. Jonas JM, Gold MS (1986). Naltrexone reverses bulimic symptoms. Lancet 8484, 807.
84. Jonas JM, Gold MS (1988a). Naltrexone treatment of bulimia: clinical and theoretical findings linking eating disorders and substance abuse. Advances in Alcohol & Substance Abuse 7, 29-37.
85. Jonas JM, Gold MS (1988b). The use of opiate antagonists in treating bulimia: a study of low-dose versus high-dose naltrexone. Psychiatry Research 24, 195-199.
86. Jordan BA, Devi LA (1999). G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399, 697-700.
87. Kales EF (1990). Macronutrient analysis of binge eating in bulimia. Physiology and Behavior 48, 837-840.
88. Kalivas PW (1993). Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Research Reviews 18, 75-113.
89. Kapur S, Sharad S, Singh RA, Gupta AK (2007). A118G polymorphism in mu opioid receptor gene (oprm1): association with opiate addiction in subjects of Indian origin. Journal of Integrative Neuroscience 6, 511-522.
90. Kas MJ, van den Bos R, Baars AM, Lubbers M, et al. (2004). Mu-opioid receptor knockout mice show diminished food-anticipatory activity. European Journal of Neuroscience 20, 1624-1632.
91. Kelley AE (1999). Functional specificity of ventral striatal compartments in appetitive behaviors. Annals of the New York Academy of Sciences 877, 71-90.
92. Kelley AE, Bakshi VP, Haber SN, Steininger TL, et al. (2002). Opioid modulation of taste hedonics within the ventral striatum. Physiology and Behaviour 76, 365-377.
93. Kelley AE, Baldo BA, Pratt WE (2005). A proposed hypothalamic-thalamic- striatal axis for the integration of energy balance, arousal, and food reward. Journal of Comparative Neurology 493, 72-85.
94. Kelley AE, Berridge KC (2002). The neuroscience of natural rewards: relevance to addictive drugs. Journal of Neuroscience 22, 3306-3311.
95. Kelley AE, Bless EP, Swanson CJ (1996). Investigation of the effects of opiate antagonists infused into the nucleus accumbens on feeding and sucrose drinking in rats. Journal of Pharmacology and Experimental Therapeutics 278, 1499-1507.
96. Kelley AE, Will MJ, Steininger TL, Zhang M, et al. (2003). Restricted daily consumption of a highly palatable food (chocolate EnsureI) alters striatal enkephalin gene expression. European Journal of Neuroscience 18, 2592-2598.
97. Kieffer BL (1995). Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cellular and Molecular Neurobiology 6, 615-635.
98. Kim EM, Welch CC, Grace MK, Billington CJ, et al. (1996). Chronic food restriction and acute food deprivation decrease mRNA levels of opioid peptides in arcuate nucleus. American Journal of Physiology 270, R1019-R1024.
99. Knight LJ, Boland FJ (1989). Restrained eating: an experimental disentanglement of the disinhibiting variables of perceived calories and food type. Journal of Abnormal Psychology 98, 412-420.
100. Knuth UA, Friesen HG (1983). Changes of beta-endorphin and somatostatin concentrations in different hypothalamic areas of female rats after chronic starvation. Life Sciences 33, 827-833.
101. Kreek MJ, LaForge KS (2007). Stress responsivity, addiction, and a functional variant of the human mu-opioid receptor gene. Molecular Interventions 7, 74-78.
102. Levin BE, Dunn-Meynell AA (2002). Defense of body weight depends on dietary composition and palatability in rats with diet-induced obesity. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 282, R46-R54.
103. Levine AS, Kotz CM, Gosnell BA (2003). Sugars and fats: the neurobiology of preference. Journal of Nutrition 133, 831S-834S.
104. Levine AS, Murray SS, Kneip J, Grace M, et al. (1982). Flavor enhances the antidipsogenic effect of naloxone. Physiology and Behavior 28, 23-25.
105. Levine AS, Weldon DT, Grace M, Cleary JP, et al. (1995). Naloxone blocks that portion of feeding driven by sweet taste in food-restricted rats. American Journal of Physiology 268, R248-R252.
106. Levine AS, Billington CJ (1997). Why do we eat? A neural systems approach. Annual Review of Nutrition 17, 597-619.
107. Lynch WC, Libby L (1983). Naloxone suppresses intake of highly preferred saccharin solutions in food deprived and sated rats. Life Sciences 33, 1909-1914.
108. MacDonald AF, Billington CJ, Levine AS (2003). Effects of the opioid antagonist naltrexone on feeding induced by DAMGO in the ventral tegmental area and in the nucleus accumbens shell region in the rat. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 285, R999-R1004.
109. MacDonald AF, Billington CJ, Levine AS (2004). Alterations in food intake by opioid and dopamine signaling pathways between the ventral tegmental area and the shell of the nucleus accumbens. Brain Research 1018, 78-85.
110. Maggio CA, Presta E, Bracco EF, Vasselli JR, et al. (1985). Naltrexone and human eating behavior: a dose-ranging inpatient trial in moderately obese men. Brain Research Bulletin 14, 657-661.
111. Majeed NH, Lasoń W, Przewłocka B, Przewłocki R (1986b). Brain and peripheral opioid peptides after changes in ingestive behaviour. Neuroendocrinology 42, 267-272.
112. Majeed NH, Przewłocka B, Wedzony K, Przewłocki R (1986a). Stimulation of food intake following opioid microinjection into the nucleus accumbens septi in rats. Peptides 7, 711-716.
113. Malcolm R, O'Neil PM, Sexauer JD, Riddle FE, et al. (1985). A controlled trial of naltrexone in obese humans. International Journal of Obesity 9, 347-353.
114. Mansour A, Hoversten MT, Taylor LP, Watson SJ, et al. (1995). The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Research 700, 89-98.
115. Marks-Kaufman R, Balmagiya T, Gross E (1984). Modifications in food intake and energy metabolism in rats as a function of chronic naltrexone infusions. Pharmacology Biochemistry and Behaviour 20, 911-916.
116. Marks-Kaufman R, Kanarek RB (1981). Modifications of nutrient selection induced by naloxone in rats. Psychopharmacology 74, 321-324.
117. Marks-Kaufman R, Plager A, Kanarek RB (1985). Central and peripheral modifications of endogenous opioid systems to nutrient selection in rats. Psychopharmacology 85, 414-418.
118. Marrazzi MA, Kinzie J, Luby ED (1995). A detailed longitudinal analysis on the use of naltrexone in the treatment of bulimia. International Clinical Psychopharmacology 10, 173-176.
119. Mathon DS, Lesscher HM, Gerrits MA, Kamal A, et al. (2005b). Increased gabaergic input to ventral tegmental area dopaminergic neurons associated with decreased cocaine reinforcement in mu-opioid receptor knockout mice. Neuroscience 130, 359-367.
120. Mathon DS, Ramakers GM, Pintar JE, Marinelli M (2005a). Decreased firing frequency of midbrain dopamine neurons in mice lacking mu opioid receptors. European Journal of Neuroscience 21, 2883-2886.
121. McElroy SL, Arnold LM, Shapira N, Keck PE, et al. (2003b). Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. American Journal of Psychiatry 160, 255-261.
122. McElroy SL, Casuto LS, Nelson EB, Lake KA, et al. (2000). Placebo-controlled trial of sertraline in the treatment of binge eating disorder. American Journal of Psychiatry 157, 1004-1006.
123. McElroy SL, Guerdjikova A, Kotwal R, Welge JA, et al. (2007a). Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. Journal of Clinical Psychiatry 68, 390-398.
124. McElroy SL, Hudson JI, Capece JA, Beyers K, et al. (2007b). Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biological Psychiatry 61, 1039-1048.
125. McElroy SL, Hudson JI, Malhorta S, Welge JA, et al. (2003a). Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial. Journal of Clinical Psychiatry 64, 807-813.
126. McElroy SL, Kotwal R, Guerdjikova A, Welge JA, et al. (2006). Zonisamide in the treatment of binge eating disorder with obesity: a placebo-controlled trial. Journal Clinical Psychiatry 67, 1897-1906. (Pubitemid 46055195)
127. Milano W, Petrella C, Casella A, Capasso A, et al. (2005). Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study. Advances in Therapy 22, 25-31.
128. Mitchell GL, Brunstrom JM (2005). Everyday dietary behaviour and the relationship between attention and meal size. Appetite 45, 344-355.
129. Mitchell JE, Christenson G, Jennings J, Huber M, et al. (1989). A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in outpatients with normal weight bulimia. Journal of Clinical Psychopharmacology 9, 94-97.
130. Mitchell JE, Gosnell BA, Roerig JL, de Zwaan M, et al. (2003). Effects of sibutramine on binge eating, hunger, and fullness in a laboratory human feeding paradigm. Obesity Research 11, 599-602.
131. Mitchell JE, Morley JE, Levine AS, Hatsukami D, et al. (1987). High-dose naltrexone therapy and dietary counselling for obesity. Biological Psychiatry 22, 35-42.
132. Mogenson GJ, Jones DL, Yim CY (1980). From motivation to action: functional interface between the limbic system and the motor system. Progress in Neurobiology 14, 69-97.
133. Morley JE, Levine AS (1980). Stress-induced eating is mediated through endogenous opiates. Science 209, 1259-1261.
134. Mucha RF, Iversen SD (1986). Increased food intake after opioid microinjections into nucleus accumbens and ventral tegmental area of rat. Brain Research 397, 214-224.
135. Novi RF, Lamberto M, Visconti P, Maurino M, et al. (1990). The role of opioid antagonists in the treatment of obesity. Results of a clinical trial with naltrexone. Minerva Endocrinologica 15, 121-123.
136. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM (2007). The epidemiology of obesity. Gastroenterology 132, 2087-2102.
137. Olszewski PK, Levine AS (2007). Central opioids and consumption of sweet tastants: when reward outweighs homeostasis. Physiology & Behavior 91, 506-512.
138. Papaleo F, Kieffer BL, Tabarin A, Contarino A (2007). Decreased motivation to eat in mu-opioid receptor-deficient mice. European Journal of Neuroscience 25, 3398-3405.
139. Pearlstein T, Spurell E, Hohlstein LA, Gurney V, et al. (2003). A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response. Archives of Women's Mental Health 6, 147-151.
140. Pecina S, Berridge KC (2000). Opioid site in nucleus accumbens shell mediates eating and hedonic 'liking' for food: map based on microinjection fos plumes. Brain Research 863, 71-86.
141. Peciña S, Berridge KC (2005). Hedonic hot spot in nucleus accumbens shell: where do mu-opioids cause increased hedonic impact of sweetness? Journal of Neuroscience 25, 11777-11786.
142. Pert CB, Snyder SH (1973). Opiate receptor: demonstration in nervous tissue. Science 179, 1011-1014.
143. Pfeiffer DG, Nikolarakis KE, Pfeiffer A (1984). Chronic blockade of opiate receptors: influence on reproduction and body weight in female rats. Neuropeptides 5, 279-282.
144. Pliner P, Herman CP, Polivy J (1990). Palatability as a determinant of eating: finickiness as a function of taste, hunger, and the prospect of good food. In: Capaldi ED, Powley TL (Eds), Taste, Experience, and Feeding: Development and Learning (pp. 210-226). Washington DC: American Psychological Association.
145. Rada P, Avena NM, Hoebel BG (2005). Daily bingeing on sugar repeatedly releases dopamine in the nucleus accumben shell. Neuroscience 143, 737-744.
146. Raingeard I, Courtet P, Renard E, Bringer J (2004). Naltrexone improves blood glucose control in type 1 diabetic women with severe and chronic eating disorders. Diabetes Care 27, 847-848.
147. Ray LA, Hutchison K (2007). Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Archives of General Psychiatry 64, 1069-1077.
148. Reas DL, Grilo CM (2008). Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity 16, 2024-2038.
149. Reid LD (1985). Endogenous opioid peptides and regulation of feeding and drinking. American Journal of Clinical Nutrition 42, 1099-1132.
150. Rudski JM, Billington CJ, Levine AS (1994). Naloxone's effects on operant responding depend upon level of deprivation. Pharmacology, Biochemistry and Behavior 49, 377-383.
151. Rudski JM, Billington CJ, LevineAS (1997). A sucrose-based maintenance diet increases sensitivity to appetite suppressant effects of naloxone. Pharmacology, Biochemistry and Behavior 58, 679-682.
152. Sahr AE, Sindelar DK, Alexander-Chacko JT, Eastwood BJ, et al. (2008). Activation of mesolimbic dopamine neurons during novel and daily limited access to palatable food is blocked by the opioid antagonist LY255582. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 295, R463-R471.
153. Shaw WN (1993). Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants. Pharmacology, Biochemistry and Behavior 46, 653-659.
154. Smith SL, Harrold JA, Williams G (2002). Diet-induced obesity increases mu opioid receptor binding in specific regions of the rat brain. Brain Research 953, 215-222.
155. Stirling LJ, Yeomans MR (2004). Effect of exposure to a forbidden food on eating in restrained and unrestrained women. International Journal of Eating Disorders 35, 59-68.
156. Striegel-Moore RH, Cachelin FM, Dohm FA, Pike KM, et al. (2001). Fairburn CG.Comparison of binge eating disorder and bulimia nervosa in a community sample. International Journal of Eating Disorders 29, 157-165.
157. Stunkard AJ (1959). Eating patterns and obesity. Psychiatry Quarterly 33, 284-295.
158. Stunkard AJ, Berkowitz R, Tanrikut C, Reiss E, et al. (1996). D-fenfluramine treatment of binge eating disorder. American Journal of Psychiatry 153, 1455-1459. (Pubitemid 26365461)
159. Tabarin A, Diz-Chaves Y, Carmona Mdel C, et al. (2005). Resistance to diet-induced obesity in mu-opioid receptor-deficient mice: evidence for a 'thrifty gene'. Diabetes 54, 3510-3516.
160. Taber MT, Zernig G, Fibiger HC (1998). Opioid receptor modulation of feeding-evoked dopamine release in the rat nucleus accumbens. Brain Research 785, 24-30.
161. Tempel A, Zukin RS (1987). Neuroanatomical patterns of the mu, delta, and kappa opioid receptors of rat brain as determined by quantitative in vitro autoradiography. Proceedings of the National Academy of Sciences USA 84, 4308-4312.
162. Town T, Abdullah L, Crawford F, Schinka J, et al. (1999). Association of a functional mu-opioid receptor allele (+118A) with alcohol dependency. American Journal of Medical Genetics 88, 458-461.
163. Waldhoer M, Bartlett SE, Whistler JL (2004). Opioid receptors. Annual Review of Biochemistry 73, 953-990.
164. Wand GS, McCaul M, Yang X, Reynolds J, et al. (2002). The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 26, 106-114.
165. Ward HG, Nicklous DM, Aloyo VJ, Simansky KJ (2006). Mu-opioid receptor cellular function in the nucleus accumbens is essential for hedonically driven eating. European Journal of Neuroscience 23, 1605-1613.
166. Welch CC, Kim EM, Grace MK, Billington CJ, et al. (1996). Palatability-induced hyperphagia increases hypothalamic Dynorphin peptide and mRNA levels. Brain Research 721, 126-131.
167. Wilfley DE, Crow SJ, Hudson JI, Mitchell JE, et al. (2007). Efficacy of
168. Will MJ, Franzblau EB, Kelley AE (2003). Nucleus accumbens mu-opioids regulate intake of a high-fat diet via activation of a distributed brain network. Journal of Neuroscience 23, 2882-2888.
169. Will MJ, Franzblau EB, Kelley AE (2004). The amygdala is critical for opioid-mediated binge eating of fat. Neuroreport 15, 1857-1860.
170. Williams KL, Winger G, Pakarinen ED, Woods JH (1998). Naltrexone reduces ethanol- and sucrose-reinforced responding in rhesus monkeys. Psychopharmacology 139, 53-61.
171. Yeomans MR, Gray RW (1996). Selective effects of naltrexone on food pleasantness and intake. Physiology and Behavior 60, 439-446.
172. Yeomans MR, Gray RW (2002). Opioid peptides and the control of human ingestive behaviour. Neuroscience and Biobehavioral Reviews 26, 713-728.
173. Yeomans MR, Wright P (1991). Lower pleasantness of palatable foods in nalmefene-treated human volunteers. Appetite 16, 249-259.
174. Yeomans MR, Wright P, Macleod HA, Critchley JA (1990). Effects of nalmefene on feeding in humans. Dissociation of hunger and palatability. Psychopharmacology 100, 426-432.
175. Zhang J, Frassetto A, Huang RR, Lao JZ, et al. (2006). The mu-opioid receptor subtype is required for the anorectic effect of an opioid receptor antagonist. European Journal of Pharmacology 545, 147-152.
176. Zhang M, Balmadrid C, Kelley AE (2003). Nucleus accumbens opioid, GABAerigc, and dopaminergic modulation of palatable food motivation: contrasting effects revealed by a progressive ratio study in the rat. Behavioural Neuroscience 117, 202-211.
177. Zhang M, Gosnell BA, Kelley AE (1998). Intake of high-fat food is selectively enhanced by mu opioid receptor stimulation within the nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics 285, 908-914.
178. Zhang M, Kelley AE (1997). Opiate agonists microinjected into the nucleus accumbens enhance sucrose drinking in rats. Psychopharmacology 132, 350-360.
179. Zhang M, Kelley AE (2000). Enhanced intake of high-fat food following striatal mu-opioid stimulation: microinjection mapping and fos expression. Neuroscience 99, 267-277.
180. Zubieta JK, Gorelick DA, Stauffer R, Ravert HT, et al. (1996). Increased mu opioid receptor binding detected by PET in cocaine dependent men is associated with cocaine craving. Nature Medicine 2, 1225-1229.